Cardiovascular Conditions Flashcards
Classifications of cholesterol types, and levels with TG
417
Classification of dyslipidemia
418
Calculating ASCVD risk
418
Select drugs and conditions that raise LDL or TG levels
418
Non-drug treatment of dyslipidemia
419
Natural products to treat dyslipidemia
419
Statin treatment intensity definitions and selection options
419/420
Equivalent doses of statins
420
Managing myalgias from statins
420
Statin drug names and doses
421
Statin safety, side effects, and monitoring
421
Statin drug interactions
421
Determining need for add-on treatments
422
Ezetimibe (Zetia)
422
Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9)
423
Bile acid sequestrants or binding resins
423
Fibrates
424
Niacin
425
Fish oils
426
Other dyslipidemia drug treatments
426
Key counseling points for dyslipidemia
427
Pathophysiology of hypertension
428/429
Screening and diagnosis of hypertension
430
Key drugs that increase blood pressure
430
Lifestyle management in hypertension
430
Natural products for hypertension
431
Guideline recommendations on treatment
431
Hypertension in pregnancy
431
Combination drug names
432
Thiazide-type diuretics
432/433
Calcium channel blockers: dihydropyridine
434
Calcium channel blockers: non dihydropyridine
435
Angiotensin-converting enzyme inhibitors (ACE)
436
Angiotensin receptor blockers (ARB)
437
Direct renin inhibitor
437
Potassium-sparing diuretics
438
Beta-blockers: B-1 selective
439
Beta-blockers: B-1 selective with nitric oxide-dep vasodilation
439
Beta-blockers: Beta nonselective
440
Beta-blockers: Beta and alpha-1 nonselective
440
Centrally acting alpha-2 adrenergic agonists
441
Direct vasodilators
441
Hypertensive urgency and emergency
442
Key counseling points for hypertension
442
Evaluation of stable ischemic HD
444
Non-drug treatment for SIHD
444
Treatment approach for SIHD
444
Antiplatelet drugs: aspirin
445
Antiplatelet drugs: clopidogrel (Plavix)
445
Dual antiplatelet therapy (DAPT)
445
Antianginal treatments
446
Nitroglycerin in SIHD
447
Key counseling points in SIHD
448
Risk factors in acute coronary syndrome
449
Diagnosis, signs, and symptoms of ACS
449/450
Comparing UA, NSTEMI, and STEMI
450
PCI or medical management
450
Drug treatment options for ACS
450
Order of operations for drugs in ACS
451
Medications to avoid in the acute setting of ACS
451
Antiplatelet drugs used in ACS
452/453
Glycoprotein IIb/IIIa receptor antagonists
454
Protease-activated receptor-1 antagonists
454
Fibrinolytic
455
Secondary prevention of ACS
456
Diagnosis of HF through ejection fraction
458
Classification of HF
458
Signs and symptoms of HF
458
Pathophysiology of HF
459
Lifestyle management of HF
459
Key drugs that cause or worsen HF
459
Types of HF
461
Initial treatment of HFrEF
460
Neprilysin inhibitor
461
Guideline-directed ACEI/ARBs
462
Guideline-directed beta-blockers
463
Aldosteron receptor antagonists
464
Sodium-glucose cotransporter 2 inhibitors (SGLT2I)
Diabetes chapter
Loop diuretics
465
Hydralazine with nitrate
466
Ivabradine
467
Digoxin
467/468
Vericiguat
468
Potassium pills
469
Action plan for HF
470
Key counseling points for HF
471
Normal cardiac conduction pathway
473
Normal cardiac action potential
474
Types of arrhythmias
474/475
Key drugs that prolong the QT interval
475
Classification of antiarrhythmic drugs
476
Types of AF
476
Rate control of AF
477
Rhythm control of AF
477
Stroke prophylaxis in AF
477
Amiodarone
478
Digoxin
479
Non-DHP CCB in AF
479
Class Ia antiarrhythmics
480/481
Class Ib antiarrhythmics
481
Class Ic antiarrhythmics
481
Class III antiarrhythmics
482
Adenosine
483
Key counseling points for arrhythmias
483
Types of strokes
484
Risk factors for stroke
485
Signs and symptoms of stroke
485
Alteplase
486
Bleeding risk with alteplase
485
Treatment of stroke
486
Secondary prevention of stroke
487/488
Types of hemorrhagic stroke
489
Treatment of ICH
489
Treatment of SAH
490